Back to top
more

Johnson & Johnson (JNJ)

(Delayed Data from NYSE)

$159.69 USD

159.69
4,765,963

+0.16 (0.10%)

Updated Oct 8, 2024 04:00 PM ET

After-Market: $159.69 0.00 (0.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value D Growth F Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 19% (47 out of 252)

Industry: Large Cap Pharmaceuticals

Better trading starts here.

Zacks News

AstraZeneca Sells Remaining Rights to its Anaesthetics Drugs

AstraZeneca (AZN) recently sold its remaining rights to its anaesthetics medicines to Aspen Group for an upfront consideration of $555 million.

    Novartis Announces Long-Term Data on Psoriasis Drug Cosentyx

    Novartis' (NVS) Cosentyx showed robust skin clearance data over a period of five years in patients with moderate-to-severe plaque psoriasis.

      Abbott's (ABT) FreeStyle Libre Gets UK Reimbursement Nod

      Abbott's (ABT) diabetes care segment to further strengthen with the FreeStyle Libre glucose monitoring system's latest U.K. national reimbursement grant.

        Integra Divests Assets to Natus, Paves Way for Codman Buyout

        Integra LifeSciences' (IART) divestment of certain neurosurgery assets to Natus Medical is part of the company's agenda to meet closing conditions toward the Codman neurosurgery business buyout.

          Achillion's HCV Partnership with J&J Terminated, Stock Falls

          Achillion Pharmaceuticals (ACHN) suffered a setback as Janssen terminated their worldwide license and collaboration arrangement on hepatitis C.

            3 Excellent Dividend ETFs for Turbulent Times

            Consider these 3 Dividend ETFs for your portfolio to battle market uncertainty.

              Swarup Gupta headshot

              Dow 30 Stock Roundup: UTX to Buy Rockwell Collins, Merck Secures EU Keytruda Approval

              The Dow endured significant losses over a holiday-shortened trading week.

                MedTech Hangs in the Balance as Obamacare Skinny Repeal Fails

                Any retention or repeal of Obamacare will actually create a vicious circle within the MedTech sector.

                  J&J (JNJ) PAH Drug's U.S. Label Expanded for Pediatric Use

                  Johnson & Johnson (JNJ), a healthcare bellwether, announced that the FDA has approved a label expansion for its oral pulmonary arterial hypertension (PAH) medicine, Tracleer.

                    The Zacks Analyst Blog Highlights: Johnson & Johnson, JPMorgan, Microsoft, Motorola, J.M. Smucker and Entergy

                    The Zacks Analyst Blog Highlights: Johnson & Johnson, JPMorgan, Microsoft, Motorola, J.M. Smucker and Entergy

                      Pfizer Presents Encouraging Eliquis Results in NVAF Patients

                      Pfizer (PFE) and partner Bristol-Myers presented data on Eliquis which showed the potential of the drug in reducing stroke and systemic embolism in NVAF patients undergoing cardioversion.

                        Biogen Alzheimer's Drug Shows Promise in Long-Term Study

                        Biogen (BIIB) announced data from a long-term study on its Alzheimer's disease candidate, aducanumab, which showed continued benefit in the rate of amyloid decline.

                          Company News For August 29, 2017

                          Companies in the news are: EXPE,BIIB,GILD,KITE,JNJ

                            J&J's (JNJ) Xarelto/Aspirin Regimen Positive in Phase III

                            J&J's (JNJ) blood thinner Xarelto shows a significant risk reduction in major cardiovascular events in patients with stable coronary and peripheral artery disease.

                              Minerva-J&J's Amendment of MIN-202 Contract Wins EU Approval

                              The EU approves of Minerva's (NERV) amendment of MIN-202 license agreement with Janssen. Per the deal, Minerva will receive an upfront payment from Janssen.

                                FDA Accepts Portola's (PTLA) BLA Resubmission for AndexXa

                                FDA acknowledges Portola's (PTLA) resubmitted BLA for AndexXa to raise hopes for an urgent need of antidotes for Factor Xa inhibitors in the market.

                                  Catalyst (CPRX) Focused on Development of Pipeline Candidates

                                  Catalyst Pharmaceuticals, Inc. (CPRX) focuses on the development of its pipeline candidates Firdapse and CPP-115.

                                    Pacira Pharmaceuticals Focuses on Exparel's Label Expansion

                                    Pacira Pharmaceuticals, Inc. (PCRX) is making efforts to expand its flagship product, Exparel, which was launched in 2012.

                                      Geron (GERN) Q2 Loss Narrows, Sales Miss Estimates, Stock Up

                                      Geron Corporation (GERN) reported narrower-than-expected loss in Q2 while sales missed estimates. Shares were up in after-hours trading.

                                        Achillion (ACHN) Q2 Loss In Line, Gains on Pipeline Update

                                        Achillion Pharmaceuticals (ACHN) second-quarter loss was in-line with estimates. The company's shares surged almost 28% in after-market trading on positive pipeline results.

                                          Drug Stocks Q2 Earnings Roster for Aug 8: ACAD, JAZZ & More

                                          A look at the pharma/biotech companies that are set to report second-quarter results on Aug 8.

                                            Pacira (PCRX) Q2 Loss Wider than Expected, Revenues Miss

                                            Pacira Pharmaceuticals, Inc. (PCRX) remains confident about the prospects of its lead drug Exparel in Q2.

                                              Pfizer (PFE) Surpasses Q2 Earnings Estimates, Misses Sales

                                              Pfizer, Inc. (PFE) beat expectations for earnings while missing the same for sales in Q2. It raised the lower end of its 2017 adjusted earnings guidance but kept the revenue expectations intact.

                                                Arpita Dutt headshot

                                                Key FDA Events to Watch Out for in Aug 2017

                                                Will the FDA follow the recommendation of its advisory panel and give its nod to Dynavax's (DVAX) hepatitis B vaccine?

                                                  The Zacks Analyst Blog Highlights: Johnson & Johnson, Merck and Co., McDonald's, Caterpillar and The Boeing Company

                                                  The Zacks Analyst Blog Highlights: Johnson & Johnson, Merck and Co., McDonald's, Caterpillar and The Boeing Company